MAIA Biotechnology, Inc.
MAIAMAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer based on mitochondrial biology. The company aims to create innovative treatments that can address difficult-to-treat cancers by exploiting vulnerabilities in mitochondrial function.
Company News
MAIA Biotechnology is developing ateganosine, a novel telomere-targeting cancer therapy for non-small cell lung cancer patients who do not respond to existing treatments, with potential to address a significant unmet medical need.
MAIA Biotechnology's lung cancer drug THIO, sequenced with Regeneron's cemiplimab, has shown promising long-term benefits in advanced non-small-cell-lung-cancer patients who failed previous treatments. The treatment has been well-tolerated with lower toxicity than standard-of-care, and some patients have continued the treatment for over 12 months...
CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board (SAB).
CHICAGO, IL, Feb. 22, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that enrollment is now complete in its Phase 2 THIO-101 go-to-market clinical trial evaluating THIO sequenced ...
MAIA Biotechnology (MAIA) reports updated results from a mid-stage study. Patients treated with its lead drug achieved disease control rates that were well-sustained compared with previous scans.
